MorphoSys stock gains after gaining U.S. antitrust approval for sale to Novartis

Published on 22 Mar 2024 on Seeking Alpha

MorphoSys rose 1% as its $2.7 billion sale to Novartis cleared U.S. antitrust regulators. The HSR...

Read the rest of the article

Start tracking your investments with Statfolio

FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancrea...

Benzinga via Yahoo Finance 23 Apr 2024

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the first quarter of...

Zacks via Yahoo Finance 23 Apr 2024

Novartis' Lutathera has received FDA approval for children aged 12 and above with certain types o...

Seeking Alpha 23 Apr 2024

Scooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesda...

Motley Fool via Yahoo Finance 23 Apr 2024

Image source: The Motley Fool. Novartis Ag (NYSE: NVS)Q1 2024 Earnings CallApr 23, 2024, 8:00 a.m...

Motley Fool via Yahoo Finance 23 Apr 2024

Investing.com 21 Apr 2024

The healthcare sector (XLV) has seen “the fruits of its labor” in higher earnings growth and help...

Seeking Alpha 19 Apr 2024

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therap...

Benzinga via Yahoo Finance 19 Apr 2024

The FDA has mandated updates to safety information for CAR-T cell therapies due to a severe risk ...

Seeking Alpha 19 Apr 2024

Biotechnology uses living organisms to develop new medicines and technologies that benefit both e...

GoBankingRates via AOL 19 Apr 2024